Data for Rivaroxaban to be presented at the ESC Congress 2010

August 28 - September 1, 2010
Stockholm, Sweden

Findings from the Phase III EINSTEIN-DVT study with Rivaroxaban have been presented during the Hot Line Session at the Annual Meeting of the European Society of Cardiology (ESC) in Stockholm, Sweden on August 31, 2010, 11:00-12:30 CEST.

On this occasion we have held a conference call for investors and analysts.


Tuesday, August 31, 2010:
Investor Conference Call on Rivaroxaban

with

Dr. Kemal Malik, Head of Global Development Bayer Schering Pharma
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)

Background Information
About Xarelto® (rivaroxaban)Download ( PDF, 412 KB ) collect
About the Rivaroxaban Clinical Trial ProgramDownload ( PDF, 822 KB ) collect
About the EINSTEIN Clinical Trial ProgramDownload ( PDF, 404 KB ) collect
About the EINSTEIN-DVT StudyDownload ( PDF, 350 KB ) collect
About the RECORD Clinical Trial ProgramDownload ( PDF, 381 KB ) collect
About the ROCKET AF StudyDownload ( PDF, 350 KB ) collect
About the ATLAS ACS Clinical Trial ProgramDownload ( PDF, 408 KB ) collect
About the MAGELLAN StudyDownload ( PDF, 410 KB ) collect
Rivaroxaban BibliographyDownload ( PDF, 455 KB ) collect
About Deep Vein Thrombosis (DVT)Download ( PDF, 333 KB ) collect
About Venous Thromboembolism (VTE)Download ( PDF, 512 KB ) collect
About Acute Coronary Syndrome (ACS)Download ( PDF, 408 KB ) collect
About Stroke Prevention in Atrial FibrillationDownload ( PDF, 388 KB ) collect
About the History of AnticoagulantsDownload ( PDF, 400 KB ) collect
Glossary of TermsDownload ( PDF, 373 KB ) collect



Last updated: January 07, 2014 Copyright © Bayer AG